Trials / Terminated
TerminatedNCT00574951
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Evaluation of AMG 706 (IND # 79,697) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Gynecologic Oncology Group · Network
- Sex
- Female
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: AMG 706 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AMG 706 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
Detailed description
OBJECTIVES: Primary * To assess the activity of AMG 706, in terms of the frequency of patients with progression-free survival for at least 6 months after initiating therapy or with an objective tumor response, in patients with persistent or recurrent ovarian epithelial, fallopian tube, or primary peritoneal carcinoma. Secondary * To determine the frequency and severity of adverse events as assessed by CTCAE v3.0. * To characterize the distribution of the progression-free and overall survival of these patients. OUTLINE: This is a multicenter study. Patients receive oral AMG 706 once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for 2 years and then every 6 months for 3 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | motesanib diphosphate |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2013-07-01
- First posted
- 2007-12-17
- Last updated
- 2018-01-11
- Results posted
- 2018-01-11
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00574951. Inclusion in this directory is not an endorsement.